Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
93.44
+0.87 (0.94%)
At close: Nov 2, 2026, 4:00 PM EST
93.46
+0.02 (0.02%)
After-hours: Nov 2, 2026, 7:32 PM EST
Rhythm Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 19 analysts polled by S&P Global, Rhythm Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $140.53. The average 1-year stock price forecast is 50.40% higher than the current stock price, while the lowest is $120 (+28.42%) and the highest is $160 (+71.23%).
Price Target: $140.53 (+50.40%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Rhythm Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 10 | 10 | 11 | 12 |
| Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Hold | 1 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 17 | 18 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Buy Maintains $143 | Buy | Maintains | $143 | +53.04% | Oct 28, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $143 | Buy | Reiterates | $143 | +53.04% | Oct 19, 2026 |
| William Blair | William Blair | Buy Initiates $206 | Buy | Initiates | $206 | +120.46% | Oct 16, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $146 → $145 | Buy | Reiterates | $146 → $145 | +55.18% | Oct 15, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $105 → $130 | Buy | Reiterates | $105 → $130 | +39.13% | Oct 12, 2026 |
Financial Forecast
Revenue This Year
315.27M
from 189.76M
Increased by 66.14%
Revenue Next Year
565.12M
from 315.27M
Increased by 79.25%
EPS This Year
-3.04
from -3.11
EPS Next Year
-0.63
from -3.04
EPS and Forward PE are based on non-GAAP adjusted numbers.